7/Having a front row seat to the bleeding edge of #Biotechnology , there is so much more to be excited about. In diagnostics, cancer/diabetes and rare disease treatments. Management of climate change and waste mitigation. In food, chemicals, and rare materials production.

8/What was previously deemed too complex, too expensive, or too rare to address, is now being reassessed, and at scale. With these new abilities, I feel hope that could potentially be equal to the problems we face.

2/@pfizer & @BioNTech_Group's promising COVID-19 RNA vaccine candidate. Unlike other vaccines—which introduce a small amount of the target virus to allow the body to familiarize the threat—the RNA vaccine delivers genetic code, telling the body to produce a sample of the virus.

3/@moderna_tx partnered with @Ginkgo (an @osfund company) fon a RNA vaccine with similar potential.

4/Where traditional vaccines count on the target virus being somewhat predictable, RNA viruses—by the nature of their design and production—are optimized for complexity and change.

5/As the virus mutates or becomes better understood, the RNA sequence can be quickly modified and a new version deployed. The solution is agile, intelligent, and utilizes the power of the human body: finally, it looks as though COVID may have a formidable opponent.

6/This is cause for celebration and reflection in how far #Biotechnology has come.

1/Since starting investing in #Biotechnology via @osfund in 2013, after selling @braintree @venmo , I’ve eagerly awaited pivotal moments that would create widespread appreciation for its unique power and necessary role in our future. One has arrived.

I spoke with @akalali about the methodical and serpentine path we took at @KernelCo to decide how to build a brain interface that could become mainstream.

RT @edoardo_danna: Here's a closer look at @KernelCo's recent live stream and their ambitious plan to put a brain-computer interface in eve…